Home/Filings/4/0001181431-10-010744
4//SEC Filing

Dennis Christopher John Wesley 4

Accession 0001181431-10-010744

CIK 0001282393other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 8:10 PM ET

Size

18.8 KB

Accession

0001181431-10-010744

Insider Transaction Report

Form 4
Period: 2010-02-16
Transactions
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    2010-02-1610,0000 total
    Exercise: $3.61Exp: 2019-12-10Common Stock (10,000 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    2010-02-164,5430 total
    Exercise: $3.62Exp: 2019-10-01Common Stock (4,543 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    2010-02-168,0530 total
    Exercise: $2.06Exp: 2019-07-01Common Stock (8,053 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    2010-02-1611,3130 total
    Exercise: $1.20Exp: 2019-04-01Common Stock (11,313 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    2010-02-1614,7290 total
    Exercise: $1.03Exp: 2019-01-02Common Stock (14,729 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    2010-02-1630,0000 total
    Exercise: $1.10Exp: 2018-12-12Common Stock (30,000 underlying)
Footnotes (7)
  • [F1]Vine Acquisition Corp. (the "Purchaser"), initiated a tender offer pursuant to Purchaser's offer to purchase all of the outstanding shares of BioForm Medical, Inc. (the "Issuer") at a cash purchase price of $5.45 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase filed with the Securities and Exchange Commission on January 15 , 2010 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of December 31, 2009, by and among, Merz GmbH & Co. KGaA, the Purchaser and the Issuer. (Continued in footnote 2).
  • [F2]The shares underlying these options, which were accelerated and became vested in connection with the closing of the Tender Offer and the fact that the reporting person ceased to be a director of the Issuer, were canceled in exchange for a cash payment of $18,400.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
  • [F3]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $8,313.69, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
  • [F4]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $27,299.67, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
  • [F5]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $48,080.25, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
  • [F6]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $65,102.18, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
  • [F7]The shares underlying these options, which were accelerated and became vested in connection with the closing of the Tender Offer and the fact that the reporting person ceased to be a director of the Issuer, were canceled in exchange for a cash payment of $130,500.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.

Issuer

BIOFORM MEDICAL INC

CIK 0001282393

Entity typeother

Related Parties

1
  • filerCIK 0001432059

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:10 PM ET
Size
18.8 KB